Have a feature idea you'd love to see implemented?
Let us know!
BCYC BICYCLE THERAPEUTICS plc
Price (delayed)
$20.26
Market cap
$1.4B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.26
Enterprise value
$513.54M
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short
Highlights
BICYCLE THERAPEUTICS's quick ratio has surged by 99% YoY and by 16% QoQ
BCYC's debt has dropped by 87% year-on-year and by 85% since the previous quarter
BCYC's equity has surged by 100% year-on-year but it is down by 4.9% since the previous quarter
BCYC's revenue is up by 49% YoY but it is down by 7% QoQ
BCYC's net income is down by 2.9% YoY
Key stats
What are the main financial stats of BCYC
Market
Valuations
Earnings
Shares outstanding
69.05M
Market cap
$1.4B
Enterprise value
$513.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.68
Price to sales (P/S)
37.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.92
Revenue
$36.9M
EBIT
-$167.14M
EBITDA
-$160.02M
Free cash flow
-$203.53M
Per share
Balance sheet
Liquidity
EPS
-$3.26
Free cash flow per share
-$2.95
Book value per share
$12.05
Revenue per share
$0.53
TBVPS
$14.45
Total assets
$996.75M
Total liabilities
$165.71M
Debt
$5.53M
Equity
$831.03M
Working capital
$909.79M
Debt to equity
0.01
Current ratio
17.13
Quick ratio
16.82
Net debt/EBITDA
5.53
Margins
Efficiency
Dividend
EBITDA margin
-433.7%
Gross margin
100%
Net margin
-450.6%
Operating margin
-532.4%
Return on assets
-20.8%
Return on equity
-27.3%
Return on invested capital
-280.9%
Return on capital employed
-17.8%
Return on sales
-453%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCYC stock price
How has the BICYCLE THERAPEUTICS stock price performed over time
Intraday
-0.49%
1 week
-10.27%
1 month
-24.12%
1 year
50.52%
YTD
12.06%
QTD
-10.47%
Financial performance
How have BICYCLE THERAPEUTICS's revenue and profit performed over time
Revenue
$36.9M
Gross profit
$36.9M
Operating income
-$196.44M
Net income
-$166.28M
Gross margin
100%
Net margin
-450.6%
BCYC's revenue is up by 49% YoY but it is down by 7% QoQ
BICYCLE THERAPEUTICS's gross profit has increased by 49% YoY but it has decreased by 7% QoQ
BCYC's net margin is up by 31% year-on-year but it is down by 8% since the previous quarter
The operating margin has grown by 21% YoY but it has contracted by 15% from the previous quarter
Growth
What is BICYCLE THERAPEUTICS's growth rate over time
Valuation
What is BICYCLE THERAPEUTICS stock price valuation
P/E
N/A
P/B
1.68
P/S
37.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.92
BICYCLE THERAPEUTICS's EPS has increased by 35% YoY and by 14% from the previous quarter
BCYC's equity has surged by 100% year-on-year but it is down by 4.9% since the previous quarter
The stock's P/B is 48% below its 5-year quarterly average of 3.2 and 16% below its last 4 quarters average of 2.0
BCYC's revenue is up by 49% YoY but it is down by 7% QoQ
The P/S is 28% more than the last 4 quarters average of 29.6 but 19% less than the 5-year quarterly average of 46.7
Efficiency
How efficient is BICYCLE THERAPEUTICS business performance
The ROE has soared by 51% YoY and by 17% from the previous quarter
The ROA has grown by 38% YoY and by 11% from the previous quarter
The company's return on invested capital fell by 37% YoY but it rose by 2.9% QoQ
BICYCLE THERAPEUTICS's ROS has increased by 29% YoY but it has decreased by 12% from the previous quarter
Dividends
What is BCYC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCYC.
Financial health
How did BICYCLE THERAPEUTICS financials performed over time
BICYCLE THERAPEUTICS's quick ratio has surged by 99% YoY and by 16% QoQ
BCYC's current ratio has surged by 98% year-on-year and by 16% since the previous quarter
BCYC's debt is 99% smaller than its equity
BCYC's equity has surged by 100% year-on-year but it is down by 4.9% since the previous quarter
BICYCLE THERAPEUTICS's debt to equity has plunged by 90% YoY and by 75% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.